Head and neck cancer (HNC) is a heterogeneous disease with advanced/recurrent disease having a poor prognosis with low survival rates. In recent years immunotherapy has shown promise as a new therapeutic pathway and Pembrolizumab has been approved as a first line agent in the treatment of recurrent or metastatic HNSCC. Targeted therapies, such as those for immune checkpoints of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have been the agents with the greatest therapeutic potential. Patients newly diagnosed with SCCHN, whether by general otolaryngologists or head and neck surgeons, are also inquiring about immunotherapy with increasing frequency. Having a fundamental understanding of immunotherapy, its current indications and future possibilities, can be useful for counseling patients. This panel is geared toward general otolaryngologist, head and neck surgeons and trainees. The panelist will provide an overview of basic immunotherapy principals, followed by more in-depth review of immunotherapy agents for the treatment of mucosal and cutaneous malignancies of the head and neck.
- Provider:American Academy of Otolaryngology – Head & Neck Surgery Foundation
- Activity Link: https://academyu.entnet.org/diweb/catalog/item?id=10925276
- Start Date: 2022-10-12 05:00:00
- End Date: 2022-10-12 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABOHNS - 1.0 Point; Credit Type(s): Self-Assessment (ABOHNS)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Community/Population Health, Learner Competence, Learner Knowledge, Learner Performance, Patient Health
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Head & Neck